论文部分内容阅读
目的探讨卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌的临床疗效。方法随机将80例进展期胃癌患者分为两组,A组:患者接受卡培他滨联合奥沙利铂治疗,B组:患者接受替吉奥联合奥沙利铂治疗,每组40例。结果 A组总有效率45%,B组总有效率50.0%,两组总有效率差异均无统计学意义。结论卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌临床疗效相当且均效果显著,不良反应较少,均在耐受范围内。
Objective To investigate the clinical efficacy of capecitabine in combination with oxaliplatin and tiotropium in combination with oxaliplatin in the treatment of advanced gastric cancer. Methods A total of 80 patients with advanced gastric cancer were randomly divided into two groups. Group A: patients received capecitabine combined with oxaliplatin; group B: patients received treatment with tiotropium combined with oxaliplatin, 40 patients in each group. Results The total effective rate was 45% in group A and 50.0% in group B, and there was no significant difference between the two groups in the total effective rate. Conclusions Both capecitabine combined with oxaliplatin and tioguanide combined with oxaliplatin have the same clinical effect and significant effect, with less adverse reactions, both within the tolerable range.